MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...

Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.

The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

The 17 sitting members of the Advisory Committee on Immunization Practices (ACIP) will be replaced by new members chosen by ...

Mosanna Therapeutics has secured $80m in a Series A funding round for advancing new nighttime nasal spray for obstructive ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.